0001628280-26-011360
SEC filingRevenue surged 33.5% to $2.8B but operating income swung to a loss of $62.1M from $58.5M profit, driven by higher expenses.
Axon Enterprise, Inc. describes itself as a technology company that provides integrated hardware and software solutions, founded in 1993 with a mission to protect life. The company serves public and private sector customers with a unified, data-driven operating system that enhances safety, accuracy, transparency, and accountability.
Axon operates in two reportable segments: Software and Services, and Connected Devices. The Software and Services segment includes cloud-based SaaS solutions such as Axon Evidence, Draft One, Axon Records, and Axon Fusus, along with professional services and on-premise licenses. The Connected Devices segment includes TASER energy devices, body cameras, in-car cameras, drones, counter-drone technologies, and related accessories and extended warranties. No revenue share percentages are disclosed for the segments.
Key products and platforms include Axon Evidence (digital evidence management), Draft One (AI report writing), Axon Records (records management), Axon Fusus (real-time crime center platform), Axon Respond (real-time operations), TASER (conducted energy devices), Axon Air (drone management), Dedrone (counter-drone), VR Training (immersive training), and Axon Fleet (in-car video systems).
Axon sells primarily through direct sales, supplemented by distribution partners and third-party resellers. Core customers include U.S. federal, state, and local governments, international governmental entities, commercial enterprises, and consumers. No single customer represented more than 10% of total net sales in any of the last three fiscal years.
The competitive landscape is highly fragmented. Key competitors vary by product category: in body cameras and digital evidence management, they include Motorola Solutions, Digital Ally, and Genetec; in RMS, Motorola Solutions, Tyler Technologies, and Mark43; in AI report writing, Abel, Mark43, and Motorola Solutions; in VR training, VirTra and InVeris; in drone management, Flock Safety and Motorola Solutions; in counter-drone, Anduril, BlueHalo, and D-Fend; in TASER for professional users, Byrna Technologies and Wrap Technologies; in personal safety, Byrna and SABRE. Competitive factors include product performance, integration, reliability, total cost of ownership, and AI capabilities.
Axon's mission drives three strategic pillars: make the bullet obsolete, reduce social conflict, and enable a fair and effective justice system. The company aims to build highly recurring, highly profitable businesses through purposeful product innovation, with a focus on AI-enhanced solutions.
As of December 31, 2025, Axon had over 5,100 full-time employees and over 1,200 temporary employees, a 24% increase in full-time employees driven by sales, R&D, and acquisitions. The company reported a regrettable attrition rate below 1.0% and employee satisfaction scores of 88% for pride in working at Axon.
For the year ended December 31, 2025, Axon's total revenue grew 33.5% to $2.78 billion, driven by strong performance across both segments. Gross margin improved slightly to 59.7% from 59.6%, but adjusted gross margin declined to 62.6% from 63.2% due to global tariffs and a higher mix of Platform Solutions revenue. Operating expenses surged 45.5% to $1.72 billion, outpacing revenue growth, resulting in an operating loss of $62.1 million compared to operating income of $58.5 million in 2024. The increase was primarily attributed to higher headcount and stock-based compensation ($610.2 million in stock-based compensation vs $382.6 million in 2024). Net income fell to $124.7 million from $377.0 million, impacted by a $38.9 million debt inducement expense from early repurchase of 2027 Notes, a $46.4 million loss on marketable securities, and higher interest expense from the issuance of $1.75 billion in Senior Notes in March 2025. This was partially offset by $186.4 million in gains from strategic investments and a $105.7 million tax benefit.
Connected Devices segment revenue increased 29.1% to $1.58 billion, accounting for 56.7% of total revenue. Growth was broad-based: TASER revenue rose 21.8% driven by TASER 10 volume; Personal Sensors grew 25.3% on AB4 adoption; Platform Solutions jumped 72.5% on counter-drone, VR training, and fleet systems. Segment gross margin declined to 48.7% from 49.4%, and adjusted gross margin fell to 51.2% from 53.6%, pressured by tariffs and mix shift toward lower-margin Platform Solutions.
Software and Services segment revenue grew 39.6% to $1.20 billion, representing 43.3% of total revenue. The increase was driven by a growing user base and higher adoption of premium add-on features. Gross margin held steady at 74.0% vs 74.1%, but adjusted gross margin improved to 77.5% from 76.8%, reflecting a favorable software mix.
Management did not provide specific financial guidance but highlighted several strategic priorities. The company expects to continue investing in headcount and technology to support growth. The recent acquisition of Carbyne Ltd. (cloud-native emergency communications) for $625 million, funded with cash on hand, signals expansion into adjacent public safety verticals. Liquidity remains strong with $1.2 billion in cash and $505.4 million in available-for-sale investments, plus a $300 million undrawn credit facility. The issuance of $1.75 billion in Senior Notes and $489.4 million in net ATM proceeds provide ample capital for acquisitions and investments. Management cautioned about ongoing tariff impacts and the dilutive effect of increased stock-based compensation. They also noted that after the settlement of all 2027 Notes in February 2026, no convertible debt remains outstanding. The shift toward higher-margin software and services is expected to continue, though near-term margin pressure from tariffs and product mix may persist.
Axon's balance sheet strength is underscored by $1.20B in cash and cash equivalents and $505.4M in short-term investments, totaling $1.71B in highly liquid assets as of December 31, 2025. Total assets surged to $7.00B from $4.47B a year earlier, driven by $1.37B in goodwill and $416.8M in strategic investments. Shareholders' equity rose to $3.24B. The debt profile transformed significantly: the company issued $1.75B in senior notes (2030 Notes at 6.125% and 2033 Notes at 6.250%), while reducing the 2027 convertible notes from $690M to $81.1M via exchange transactions. Total debt principal reached $1.83B, but the net leverage ratio remained low at 0.15x. Deferred tax assets netted $359.8M.
Axon disclosed substantial purchase commitments: $1.2B in open purchase orders with vendors and $154.9M remaining under a six-year cloud hosting agreement (total commitment $425M). Other purchase obligations aggregated $156.7M. The company also maintains $8.9M in outstanding letters of credit and $8.1M in surety bonds. Cloud service fees alone were $110.6M in fiscal 2025. These commitments reflect aggressive scaling of infrastructure and supply chain.
No share repurchases occurred in 2025; $16.3M remains authorized under the 2016 program. No dividends are paid. Capex totaled $136.3M (4.9% of sales), up from $78.8M, primarily for headquarters development ($33.6M in construction-in-process). Debt issuance of $1.75B was partially offset by $608.9M in convertible note repurchases. The company also utilized an ATM equity offering, generating $489.4M in net proceeds from 0.7M shares. A $300M revolving credit facility (undrawn as of year-end) provides additional liquidity.
Axon operates two segments: Connected Devices ($1.58B revenue, +29.1% YoY) and Software and Services ($1.20B, +39.6% YoY). The CODM evaluates profitability via adjusted gross margin: Connected Devices $807.6M, Software and Services $931.5M. Revenue remains heavily U.S.-centric (83% in 2025), with international at 17% ($474.5M). No single country outside the U.S. exceeded 10% of total sales. The segment realignment (effective Jan 2025) recast prior periods to the new structure.
Axon's business is heavily dependent on continued acceptance by law enforcement agencies, particularly in the U.S., and on sales of its conducted energy devices (CEDs). Any reduction in demand, whether due to negative publicity, product performance issues, or budget constraints, could materially harm financial results. The company also faces risks from rapid technological change, especially in AI, where uncertainty in development, deployment, and regulation could lead to defects, bias, or increased costs. Negative publicity, whether merited or not, can rapidly damage brand reputation and sales.
Supply chain disruptions are a key concern, with dependence on single or sole-source components, exposure to tariffs (especially from China, Mexico, and Canada), and potential semiconductor shortages. Cybersecurity remains a top risk, as breaches could lead to unauthorized access to sensitive customer data, legal liability, and loss of trust. The company also highlights risks from catastrophic events, product defects, and the challenges of international operations, including export controls and varying local laws.
The shift to subscription billing introduces credit risk and delayed cash collections. Government customers' budgetary cycles and political constraints can delay or cancel contracts. Gross margin is subject to fluctuations from product mix, cost structure, and acquisitions. The company also notes risks from foreign currency fluctuations, tax uncertainties, and the potential for impairment of investments.
Product liability claims, particularly related to CED use, could result in significant judgments. Intellectual property infringement claims and the inability to protect proprietary technology could erode competitive advantage. Compliance with evolving laws on data privacy, AI, and firearms regulation (for TASER 10) is costly and uncertain. The company also faces risks from government procurement regulations and ESG-related disclosures.
Axon's indebtedness, including convertible notes and a credit facility, requires significant cash for servicing. Restrictive covenants could limit operational flexibility. The note hedge and warrant transactions may cause dilution or impact stock price. Counterparty risk exists with financial institutions involved in these transactions.
The cash flow statement excerpt is incomplete, as it cuts off mid-line under depreciation and amortization. Based on available data for FY2025, net income was $124.7 million, a significant decline from $377.0 million in FY2024. Key non-cash adjustments include stock-based compensation of $634.2 million (up from $382.6 million) and a gain on strategic investments and marketable securities of $139.9 million (compared to a gain of $283.2 million in FY2024). A notable one-time item is the debt inducement expense of $38.9 million. Without the total operating, investing, and financing cash flow figures, it is impossible to calculate free cash flow or assess capital allocation. The high stock-based compensation suggests that operating cash flow could be substantially higher than net income, but the exact CFO amount is unavailable. Analysts should refer to the full filing for complete cash flow details.
Note: The provided excerpt is truncated; therefore, key metrics like total operating cash flow, capex, and free cash flow are not disclosed and cannot be inferred.